Improving treatment satisfaction and other patient-reported outcomes in people with Type 2 diabetes: the role of once-daily insulin glargine. June 20, 2008 Read More »
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. June 1, 2008 Read More »
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. March 29, 2008 Read More »
Design of a measure of satisfaction with treatment for Macular Degeneration (MacTSQ) October 30, 2007 Read More »
The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. October 10, 2007 Read More »
The Dose Adjustment For Normal Eating (DAFNE) Trial: improvements in HbA1c still apparent and quality of life benefits well maintained at 4-year follow-up. February 20, 2007 Read More »
Quality of Life and Health Economic Assessments of Age-Related Macular Degeneration. January 1, 2007 Read More »
Detailed analysis of treatment satisfaction with oral agents plus either basal insulin glargine or mealtime analogue insulin in patients with Type 2 diabetes – the APOLLO study. November 7, 2006 Read More »
Treatment satisfaction in patients with Type 2 diabetes: basal insulin plus oral agents versus twice-daily premixed insulin alone – analyses by country. November 7, 2006 Read More »
Feedback on the FDA’s February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures October 9, 2006 Read More »
